Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome.

Verhave JC, Westra D, van Hamersvelt HW, van Helden M, van de Kar NC, Wetzels JF.

Neth J Med. 2013 Sep;71(7):342-7.

2.

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.

Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP.

Transplant Proc. 2012 Dec;44(10):3037-40. doi: 10.1016/j.transproceed.2012.07.141.

PMID:
23195022
3.

Kidney transplantation in atypical haemolytic uraemic syndrome (aHUS): a cheap way out?

Bemelman FJ, ten Berge IJ.

Neth J Med. 2013 Sep;71(7):339-41. No abstract available.

4.

Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.

Zlamy M, Hofer J, Elias J, Vogel U, Frosch M, Jungraithmayr T, Zimmerhackl LB, Prelog M.

Pediatr Transplant. 2012 Sep;16(6):E246-50. doi: 10.1111/j.1399-3046.2011.01585.x. Epub 2011 Oct 4.

PMID:
21967634
5.

[De novo hemolytic uremic syndrome in a kidney-pancreas recipient in the postoperative period].

Gutiérrez de la Fuente C, Sola E, Alférez MJ, Navarro A, Cabello M, Burgos D, González Molina M.

Nefrologia. 2004;24 Suppl 3:3-6. Spanish.

6.

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.

Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S.

Pediatr Nephrol. 2011 Aug;26(8):1325-9. doi: 10.1007/s00467-011-1879-9. Epub 2011 May 10.

PMID:
21556717
7.

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.

Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.

Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011. Epub 2013 Sep 8.

PMID:
24021908
8.

Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.

Ojogho O, Sahney S, Cutler D, Baron PW, Abdelhalim FM, James S, Zuppan C, Franco E, Concepcion W.

Pediatr Transplant. 2005 Feb;9(1):80-3.

PMID:
15667617
9.

Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.

Noris M, Remuzzi G.

Curr Opin Nephrol Hypertens. 2013 Nov;22(6):704-12. doi: 10.1097/MNH.0b013e328365b3fe. Review.

PMID:
24076560
10.

Atypical hemolytic uremic syndrome recurrence after kidney transplantation.

Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N.

Transplantation. 2014 Dec 15;98(11):1205-12. doi: 10.1097/TP.0000000000000200.

PMID:
24933457
11.

Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation.

Zuber J, Le Quintrec M, Morris H, Frémeaux-Bacchi V, Loirat C, Legendre C.

Transplant Rev (Orlando). 2013 Oct;27(4):117-25. doi: 10.1016/j.trre.2013.07.003. Epub 2013 Aug 12. Review.

PMID:
23937869
12.

Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.

Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C; French Study Group for Atypical HUS.

Am J Transplant. 2012 Dec;12(12):3337-54. doi: 10.1111/j.1600-6143.2012.04252.x. Epub 2012 Sep 7.

13.

Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol.

Rahamimov R, Yussim A, After T, Lustig S, Bar-Nathan N, Shaharabani E, Shapira Z, Shabthai E, Mor E.

Transplant Proc. 2003 Mar;35(2):653-4. No abstract available.

PMID:
12644082
14.

Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case with Atypical Hemolytic Uremic Syndrome.

Kasapoğlu U, Ruhi Ç, Tuğcu M, Boynueğri B, Titiz İ, Hançer VS, Apaydın S.

Ann Transplant. 2015 Dec 1;20:714-9. Review.

15.

Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.

Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS.

Health Technol Assess. 2005 May;9(21):1-179, iii-iv. Review.

16.

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.

Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.

Intern Med J. 2015 Oct;45(10):1054-65. doi: 10.1111/imj.12864.

PMID:
26247170
17.

Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation.

Tran H, Chaudhuri A, Concepcion W, Grimm PC.

Pediatr Nephrol. 2014 Mar;29(3):477-80. doi: 10.1007/s00467-013-2630-5. Epub 2013 Nov 13.

PMID:
24221349
18.

Posttransplant recurrence of atypical hemolytic uremic syndrome.

Valoti E, Alberti M, Noris M.

J Nephrol. 2012 Nov-Dec;25(6):911-7. doi: 10.5301/jn.5000146. Review.

PMID:
22760880
19.

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G.

Nat Rev Nephrol. 2012 Nov;8(11):643-57. doi: 10.1038/nrneph.2012.214. Epub 2012 Oct 2. Review.

PMID:
23026949
20.

Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.

Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber AO.

Transplant Proc. 2001 Feb-Mar;33(1-2):1701-3. No abstract available.

PMID:
11267477
Items per page

Supplemental Content

Write to the Help Desk